What is the official website of LEO Pharma Italia ?

The official website of LEO Pharma Italia is http://www.leo-pharma.it.

What is LEO Pharma Italia's cybersecurity risk score?

LEO Pharma Italia has an AI-generated cybersecurity risk score of 757 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has LEO Pharma Italia experienced?

According to Rankiteo, LEO Pharma Italia currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has LEO Pharma Italia been affected by any supply chain cyber incidents ?

According to Rankiteo, LEO Pharma Italia has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does LEO Pharma Italia have SOC 2 Type 1 certification ?

According to Rankiteo, LEO Pharma Italia is not certified under SOC 2 Type 1.

Does LEO Pharma Italia have SOC 2 Type 2 certification ?

According to Rankiteo, LEO Pharma Italia does not hold a SOC 2 Type 2 certification.

Does LEO Pharma Italia comply with GDPR ?

According to Rankiteo, LEO Pharma Italia is not listed as GDPR compliant.

Does LEO Pharma Italia have PCI DSS certification ?

According to Rankiteo, LEO Pharma Italia does not currently maintain PCI DSS compliance.

Does LEO Pharma Italia comply with HIPAA ?

According to Rankiteo, LEO Pharma Italia is not compliant with HIPAA regulations.

Does LEO Pharma Italia have ISO 27001 certification ?

According to Rankiteo,LEO Pharma Italia is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does LEO Pharma Italia operate in ?

LEO Pharma Italia operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does LEO Pharma Italia have ?

LEO Pharma Italia employs approximately None employees people worldwide.

Does LEO Pharma Italia own any subsidiaries ?

LEO Pharma Italia presently has no subsidiaries across any sectors.

How many LinkedIn followers does LEO Pharma Italia have ?

LEO Pharma Italia's official LinkedIn profile has approximately 14,297 followers.

What is the NAICS classification code for LEO Pharma Italia ?

LEO Pharma Italia is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does LEO Pharma Italia have a Crunchbase profile ?

No, LEO Pharma Italia does not have a profile on Crunchbase.

Does LEO Pharma Italia have a LinkedIn profile ?

Yes, LEO Pharma Italia maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/leo-pharma-italia.

How many cybersecurity incidents has LEO Pharma Italia experienced ?

As of August 16, 2026, Rankiteo reports that LEO Pharma Italia has not experienced any cybersecurity incidents.

How many peer or competitor companies does LEO Pharma Italia have ?

LEO Pharma Italia has an estimated 5,727 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

LPI

Boost Score +25 with badge (5 left)

757

/1000

Fair

782

/1000

Fair

LEO Pharma Italia Vendor Cyber Rating & Cyber Score

leo-pharma.it

Add Your Compliance Badge

LEO Pharma è un’azienda farmaceutica danese, fondata nel 1908, leader a livello mondiale nella cura delle patologie dermatologiche. LEO Pharma vanta una presenza in più di 60 Paesi e commercializza i suoi prodotti in oltre 130 mercati. L’azienda ha dedicato decenni alla ricerca e allo sviluppo di farmaci e soluzioni per la cura di patologie cutanee. La sua mission, infatti, è quella di aiutare le persone ad avere una pelle più sana, diventando al contempo partner di riferimento per Dermatologi e Medici di Medicina Generale. A caratterizzare LEO Pharma è inoltre la centralità del paziente e la sua attenzione verso i suoi bisogni, non solo attraverso soluzioni terapeutiche, ma anche attraverso la diffusione di una cultura della salute

LPI A.I CyberSecurity Scoring

Scoring History

LPI

LEO Pharma Italia CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

LPI Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for LPI

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for LEO Pharma Italia in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for LEO Pharma Italia in 2026.

Incident Types LPI vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for LEO Pharma Italia in 2026.

Incident History - LPI (X = Date, Y = Severity)

Loading…

SUBSIDIARY

LEO Pharma Italia Subsidiaries

LPI

Pharmaceutical Manufacturing

Website: http://www.leo-pharma.it

Company Size: 51-200 employees

LEO Pharma FrancePharmaceutical Manufacturing

LEO PharmaPharmaceutical Manufacturing

LEO Innovation Lab - LEO Ventures A/SPharmaceutical Manufacturing

LEO Pharma CanadaPharmaceutical Manufacturing

LEO Pharma UK/IEPharmaceutical Manufacturing

Loading…

LEO Pharma Italia Similar Companies

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Loading…

NEWS

LEO Pharma Italia CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-19917

SUMMARY

A flaw has been found in code-projects Online Food Order System 1.0. The impacted element is an unknown function of the file delete_food_items1.php. Executing a manipulation of the argument checkbox can lead to sql injection. The attack can be executed remotely. The exploit has been published and may be used.

Published

Date2026-08-15

Updated

Date2026-08-15

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-74767

SUMMARY

Pandora contains a denial-of-service vulnerability in its handling of DAA (Direct Access Archive) files. When extracting the internal ISO image from a DAA archive, compressed chunks were decompressed using zlib.decompress() without enforcing a limit on the resulting uncompressed data. An attacker able to submit a crafted DAA file containing highly compressed data could cause Pandora to decompress a relatively small input into a very large amount of data in memory. Because the decompressed chunks are accumulated to construct the internal ISO image, this could result in excessive memory consumption and potentially CPU exhaustion, causing the extraction worker to become unresponsive, terminate, or affect the availability of the Pandora service. The patch introduces bounded decompression using decompressobj().decompress() with max_extracted_filesize, verifies the cumulative size of decompressed chunks, and raises a dedicated ZipBomb exception when the configured limit is exceeded. Pandora then aborts extraction and reports the file as too large.

Published

Date2026-08-15

Updated

Date2026-08-15

RISK INFORMATION (Score: )

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/pandora-analysis/pandora/commit/f4294a873f86fbf2569c289e329fff2f52ca50c9

CVE-2026-74764

SUMMARY

Pandora contains a path traversal vulnerability in its TAR archive extraction functionality. When processing a submitted TAR archive, the extractor passed archive member names directly to Python's tarfile.TarFile.extract() without applying an extraction filter. An attacker able to submit a specially crafted TAR archive containing malicious member paths, such as paths using ../ sequences or absolute paths, could cause extracted files to be written outside the intended extraction directory. This may allow the attacker to overwrite files accessible to the Pandora worker process and could potentially result in application compromise, arbitrary code execution, or denial of service depending on the files targeted and the privileges of the Pandora process. The vulnerability is corrected by using Python's filter='data' extraction filter, which rejects or sanitizes dangerous TAR members, including paths that escape the destination directory and unsafe link targets. The weakness corresponds to MITRE's general path traversal category, which includes archive extraction cases where attacker-controlled filenames cause files to be written outside the intended directory.

Published

Date2026-08-15

Updated

Date2026-08-15

RISK INFORMATION (Score: )

cvss4

Base Score: 10.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/pandora-analysis/pandora/commit/186b58d41e04248a154d274fffb5813e7fa2012e

CVE-2026-73055

SUMMARY

Shescape before 2.1.15 (and 3.0.0 before 3.0.2) fails to properly escape tilde (~) characters in assignment contexts on Unix systems where the shell is explicitly configured to "sh" or true and /bin/sh points to BusyBox. Using the escape and escapeAll APIs with untrusted input in an assignment prefixed to a command, an attacker can inject a tilde payload to disclose the user's home directory location and, depending on usage, alter the location on which a command operates.

Published

Date2026-08-15

Updated

Date2026-08-15

RISK INFORMATION (Score: 4.8)

cvss3

Base Score: 4.8

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:L/A:N

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

2.2

REFERENCES

CVE-2026-73054

SUMMARY

SiYuan versions before v3.7.4 contain an authentication bypass vulnerability in the WebSocket endpoint caused by differential parsing of query parameters between authentication exemption and session quarantine checks. Unauthenticated attackers can craft a malicious WebSocket URI with duplicated query parameters to bypass access auth code validation and receive the live kernel event stream including document identifiers, titles, and operation logs.

Published

Date2026-08-15

Updated

Date2026-08-15

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…